AstraZeneca is committing a staggering $50 billion into U.S. operations, encompassing R&D, manufacturing, and supply chain expansion by 2030. This is one of the largest US pharma infrastructure investments in recent history.
- Pfizer and Moderna have also announced intentions to expand their biomanufacturing footprint within the U.S. in recent quarters.
- Ten biopharma firms have collectively pledged over $120 billion in new or expanded U.S. operations since Q2 of 2024, per BioPharma Dive.
So why would companies commit to building here while also facing pricing headwinds?
